Amarin said in a statement that this is the first drug in the class to be recommended by NICE for cardiovascular risk reduction. The final guidance is expected to be published on 20 July.

“At Amarin, we continue to invest in the science behind VASCEPA/VAZKEPA to further explore the potential mechanistic activities of EPA, administered clinically in the form of our i Amarin incurs ...